GlassScriptPhysician profile
Alla Tsimerman
NPI 1376831545
$2,897.15
in general payments reported to CMS, 2019-2025
31 companies · $351 in 2025
The $351 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $241 · 2022: $886 · 2023: $1,258 · 2024: $160 · 2025: $351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,770.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,769.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $535.89 | 2022-2025 | Ubrelvy, Vraylar, Qulipta |
| Revance Therapeutics, INC. | $258.26 | 2024-2025 | Daxi, Daxxify |
| Merz North America, INC. | $252.37 | 2023-2025 | Xeomin |
| Janssen Pharmaceuticals, INC | $222.91 | 2021-2022 | |
| Pfizer INC. | $201.62 | 2021-2023 | |
| Amgen INC. | $193.11 | 2021-2023 | Otezla, Repatha, Evenity |
| Almatica Pharma LLC | $167.81 | 2022-2023 | Loreev Xr, Sertraline Hcl, Gralise |
| Glaxosmithkline, LLC. | $136.74 | 2022-2023 | Arexvy, Shingrix, Trelegy Ellipta |
| E.R. Squibb & Sons, L.L.C. | $130.89 | 2023 | Camzyos |
| Novartis Pharmaceuticals Corporation | $102.95 | 2022-2024 | |
| Exact Sciences Corporation | $95.24 | 2023 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $79.15 | 2022 | |
| Idorsia Pharmaceuticals US INC | $64.24 | 2023 | Quviviq |
| Xeris Pharmaceuticals, INC. | $59.08 | 2022-2023 | Gvoke Hypopen |
| Mylan Specialty L.P. | $48.53 | 2021-2023 | Yupelri |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $39.43 | 2023 | Gemtesa |
| Amarin Pharma, INC. | $36.51 | 2022-2023 | |
| Lilly USA, LLC | $32.89 | 2022 | |
| Eisai INC. | $27.89 | 2021 | |
| Galderma Laboratories, L.P. | $24.13 | 2025 | |
| Esperion Therapeutics, INC. | $22.23 | 2022 | |
| Radius Health, INC. | $20.04 | 2022 | |
| Boston Scientific Corporation | $19.72 | 2023 | Watchman Access System |
| Astrazeneca Pharmaceuticals LP | $17.97 | 2023 | Wainua |
| Merck Sharp & Dohme LLC | $17.41 | 2022 | |
| Sunovion Pharmaceuticals INC. | $17.06 | 2022 | |
| Novo Nordisk INC | $15.61 | 2023 | Wegovy |
| Hologic Sales and Service, LLC | $15.20 | 2023 | Thinprep 2000 Processor, Aptima |
| Currax Pharmaceuticals LLC | $14.98 | 2022 | |
| Biogen, INC. | $14.76 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $12.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alla Tsimerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.